Compounds and combinations thereof for treating neurological and psychiatric conditions
Herriot Tabuteau, New York, NY (US)
Assigned to ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed by ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed on Sep. 27, 2023, as Appl. No. 18/475,841.
Application 18/475,841 is a continuation of application No. 17/929,147, filed on Sep. 1, 2022, granted, now 11,779,579.
Application 17/929,147 is a continuation of application No. 17/547,050, filed on Dec. 9, 2021, granted, now 11,433,067, issued on Sep. 6, 2022.
Application 17/547,050 is a continuation in part of application No. 17/066,310, filed on Oct. 8, 2020, granted, now 11,229,640, issued on Jan. 25, 2022.
Application 17/066,310 is a continuation in part of application No. 16/822,697, filed on Mar. 18, 2020, granted, now 11,090,300, issued on Aug. 17, 2021.
Application 17/066,310 is a continuation in part of application No. 16/817,119, filed on Mar. 12, 2020, granted, now 10,813,924, issued on Oct. 27, 2020.
Application 16/822,697 is a continuation in part of application No. 16/359,958, filed on Mar. 20, 2019, granted, now 10,881,657, issued on Jan. 5, 2021.
Application 16/817,119 is a continuation in part of application No. 16/359,996, filed on Mar. 20, 2019, granted, now 10,688,066, issued on Jun. 23, 2020.
Application 16/359,958 is a continuation in part of application No. 15/821,563, filed on Nov. 22, 2017, granted, now 10,512,643, issued on Dec. 24, 2019.
Application 15/821,563 is a continuation in part of application No. 15/645,939, filed on Jul. 10, 2017, granted, now 9,867,819, issued on Jan. 16, 2018.
Application 15/645,939 is a continuation in part of application No. 15/263,138, filed on Sep. 12, 2016, granted, now 9,700,553, issued on Jul. 11, 2017.
Application 15/263,138 is a continuation of application No. 15/164,746, filed on May 25, 2016, granted, now 9,457,023, issued on Oct. 4, 2016.
Application 15/164,746 is a continuation in part of application No. 14/879,002, filed on Oct. 8, 2015, granted, now 9,375,429, issued on Jun. 28, 2016.
Application 14/879,002 is a continuation of application No. 14/554,988, filed on Nov. 26, 2014, granted, now 9,205,083, issued on Dec. 8, 2015.
Application 14/554,988 is a continuation of application No. 14/550,618, filed on Nov. 21, 2014, granted, now 9,198,905, issued on Dec. 1, 2015.
Application 14/550,618 is a continuation in part of application No. PCT/US2014/064184, filed on Nov. 5, 2014.
Claims priority of provisional application 62/645,751, filed on Mar. 20, 2018.
Claims priority of provisional application 62/576,538, filed on Oct. 24, 2017.
Claims priority of provisional application 61/900,354, filed on Nov. 5, 2013.
Prior Publication US 2024/0024309 A1, Jan. 25, 2024
1. A method of treating depression comprising: orally administering a dosage form daily to a human being suffering from depression; wherein the dosage form comprises dextromethorphan or a pharmaceutically acceptable salt thereof, and trazodone or a pharmaceutically acceptable salt thereof; wherein the dextromethorphan and the trazodone are the only therapeutically active agents in the dosage form; and wherein the human being is an extensive metabolizer of dextromethorphan.